-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: The Promise of Antibody-Drug Conjugates in Gynecologic Malignancies_Bhavana Pothuri, MD
33:38
-
Robert Coleman, MD; Texas Oncology; 5Live #SGO22
6:07
Key Insights from the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting #SGO22
-
Elisabeth Driver, MD; Stanford Cancer Institute; 5Live #SGO22
3:36
Key Insights from the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting #SGO22
-
Addressing Disparities in Cancer Care and Incorporating Precision Medicine for Minority Populations_Gynecologic Malignancies_Cervical Cancer_Rebecca Perkins, MD, MSc
45:52
-
Robert L. Coleman, MD; US Oncology Research; 5Live; #ASCO2021
10:41
-
Thomas J. Herzog, MD; University of Cincinnati Cancer Center; 5Live; #ASCO21
8:12
-
Kathleen Moore, MD; Stephenson Cancer Center at the University of Oklahoma; 5Live; #ASCO2021
7:47
-
Michael J. Birrer, MD, PhD; University of Arkansas for Medical Sciences; 5Live; #ASCO2021
8:00
-
Bhavana Pothuri, MD; NYU Langone Health at Perlmutter Cancer Center; 5Live; #ASCO2021
7:14
-
Ritu Salani, MD, MBA; David Geffen School of Medicine at UCLA; 5Live; #ASCO2021
4:35
-
Dana Chase, MD, FACOG; Arizona Oncology; 5Live; #SGO21
9:45
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company